kabutan

TMS Co., Ltd.(4891) Summary

4891
TSE Growth
TMS Co., Ltd.
151
JPY
+1
(+0.67%)
Jan 29, 3:30 pm JST
0.98
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
151.1
Jan 29, 3:20 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.32
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
149 JPY 0.97 USD
Previous Close Jan 28
150 JPY 0.98 USD
High Jan 29, 11:07 am
151 JPY 0.98 USD
Low Jan 29, 9:01 am
147 JPY 0.96 USD
Volume
250,000
Trading Value
0.04B JPY 0.24M USD
VWAP
149.46 JPY 0.98 USD
Minimum Trading Value
15,100 JPY 98 USD
Market Cap
6.87B JPY 0.05B USD
Number of Trades
92
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
405
1-Year High Feb 7, 2025
8,569
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 3,475,800
Jan 16, 2026 0 3,443,700
Jan 9, 2026 0 3,166,100
Dec 26, 2025 5,000 3,289,000 657.80
Dec 19, 2025 0 3,226,400
Company Profile
TMS Co., Ltd. is a drug discovery bioventure originating from Tokyo University of Agriculture and Technology. The company has partnered with US-based Biogen for its acute ischemic stroke drug candidate.
Sector
Pharmaceuticals
TMS Co., Ltd., a drug discovery bioventure spun off from Tokyo University of Agriculture and Technology, focuses its business on developing TMS-007, a drug candidate for acute ischemic stroke. TMS-007 possesses both thrombolytic and anti-inflammatory properties and has shown promising results in Phase IIa clinical trials. The company has partnered with Hong Kong-based JIXING and retains development and marketing rights for Japan. TMS Co., Ltd. also has multiple pipelines, including TMS-008 for acute kidney injury and cancer cachexia, and JX09, a candidate for hypertension treatment. The company's growth strategy involves in-licensing and developing drug seeds from academia through collaborative research with universities and other institutions, aiming to expand into the global market.